Literature DB >> 26672915

Morcellation of undiagnosed uterine sarcoma: A critical review.

Giorgio Bogani1, Valentina Chiappa2, Antonino Ditto2, Fabio Martinelli2, Cristina Donfrancesco2, Alice Indini2, Domenica Lorusso2, Francesco Raspagliesi2.   

Abstract

In the recent decades, laparoscopy has replaced open abdominal procedures in the setting of gynecologic surgery. Extraction of large specimens (e.g., large uteri or myomas) following operative laparoscopy is technically challenging. Technological attempts allow the removal of large and solid pelvic masses via small abdominal incisions (using instruments called morcellators), thus reducing unnecessary laparotomies and improving short-term patients' outcomes. However, morcellation of undiagnosed uterine malignancies may lead to worse survival outcomes. Therefore, the Food and Drug Administration (FDA) warns about the use of power morcellators, thus causing ongoing concerns on the applicability of minimally invasive approaches for myomectomy and the removal of large uteri. In the present review, we sought to assess pro and cons regarding minimally invasive morcellation. This review will discuss the effects of morcellation of undiagnosed uterine malignancies, focusing on possible techniques for preoperative detection of uterine sarcoma and for avoiding intra-abdominal dissemination of potentially malignant tissues. Further efforts are necessary in order to identify tools to make a more accurate and reliable preoperative diagnosis of uterine masses. However, on the light of the current evidence, intra-abdominal morcellation should be banned from clinical practice.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Hysterectomy; Laparoscopy; Minimally invasive; Morcellation; Robotic; Sarcoma

Mesh:

Year:  2015        PMID: 26672915     DOI: 10.1016/j.critrevonc.2015.11.015

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  Placenta accreta following hysteroscopic myomectomy.

Authors:  Mie Tanaka; Shinya Matsuzaki; Satoko Matsuzaki; Aiko Kakigano; Keiichi Kumasawa; Yutaka Ueda; Masayuki Endo; Tadashi Kimura
Journal:  Clin Case Rep       Date:  2016-04-20

2.  Morcellation of apparent benign uterine myoma: assessing risk to benefit ratio.

Authors:  Giorgio Bogani; Valentina Chiappa; Antonino Ditto; Fabio Martinelli; Mauro Signorelli; Domenica Lorusso; Francesco Raspagliesi
Journal:  J Gynecol Oncol       Date:  2016-04-05       Impact factor: 4.401

3.  Frequency of uterine sarcomas in patients admitted for uterine fibroid surgery.

Authors:  Liselotte Mettler; Nicolai Maass; Khulkar Abdusattarova; Astrid Dempfle; Ibrahim Alkatout
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-02-07

4.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in seven patients with peritoneal sarcomatosis from uterine sarcoma.

Authors:  Armando Sardi; Carlos A Muñoz-Zuluaga; Michelle Sittig; Teresa Diaz-Montes
Journal:  Clin Case Rep       Date:  2018-05-02

5.  Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma.

Authors:  S Cabrera; V Bebia; U Acosta; S Franco-Camps; L Mañalich; A García-Jiménez; A Gil-Moreno
Journal:  Clin Transl Oncol       Date:  2020-11-18       Impact factor: 3.405

6.  The impact of morcellation on survival outcomes of undiagnosed uterine sarcoma.

Authors:  Francesco Raspagliesi; Giorgio Bogani; Domenica Lorusso
Journal:  Gynecol Oncol Rep       Date:  2018-01-28

7.  Transumbilical extraction of 151-300-g myomas without morcellator versus conventional laparoscopic myomectomy with power morcellator.

Authors:  Kyoka Amemiya; Kazushige Adachi; Naoko Sasamoto; Yoshimitsu Yamamoto
Journal:  Gynecol Minim Invasive Ther       Date:  2017-07-08

8.  Increased LDH5/LDH1 ratio in preoperative diagnosis of uterine sarcoma with inconclusive MRI and LDH total activity but suggestive CT scan: a case report.

Authors:  Antonio Mollo; Antonio Raffone; Antonio Travaglino; Annalisa Di Cello; Gabriele Saccone; Fulvio Zullo; Giuseppe De Placido
Journal:  BMC Womens Health       Date:  2018-10-19       Impact factor: 2.809

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.